Current medical research and opinion
-
Vedolizumab is an antibody targeting α4β7 integrin used in the treatment of ulcerative colitis (UC). Patients are commonly prescribed higher-than-standard doses if treatment response is inadequate, but little is known about the drivers and impact of increased dosing. Our objective was to use real-world data to describe vedolizumab dosages in current clinical practice, patient characteristics, physicians' reasons for prescribing vedolizumab, and physician treatment satisfaction. ⋯ Over 10% of patients were receiving a higher-than-standard dose of vedolizumab, but despite this were found to have suboptimal clinical outcomes and low physician satisfaction.
-
Lack of energy, fatigue, debility are often seen in depression and hardly respond to treatment. Finding some biomarkers for these symptoms may be important for diagnosis and treatment. We aimed to investigate the possible relationship between depression and energy-related molecules irisin, adropin and preptin. ⋯ We found decreased serum irisin, adropin and preptin levels in depression. Our results may support investigation of irisin, adropin and preptin as biomarkers for depression but it might be more meaningful to evaluate these biomarkers in a long-term follow-up.